Equities

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,671.50
  • Today's Change7.50 / 0.45%
  • Shares traded820.20k
  • 1 Year change+23.13%
  • Beta0.6195
Data delayed at least 20 minutes, as of Nov 22 2024 05:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

  • Revenue in JPY (TTM)302.56bn
  • Net income in JPY26.13bn
  • Incorporated1925
  • Employees3.74k
  • Location
    Santen Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
  • Phone+81 676648621
  • Fax+81 663593827
  • Websitehttps://www.santen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mochida Pharmaceutical Co Ltd104.51bn4.53bn122.15bn1.52k25.520.895216.441.17127.75127.752,945.163,641.810.66391.803.4268,662,940.002.884.373.415.3149.6152.474.346.713.50--0.0045.16-0.3641-1.26-31.61-11.6310.91-1.21
Torii Pharmaceutical Co Ltd58.84bn5.28bn136.94bn583.0025.331.1124.042.33187.71187.712,093.334,271.840.44112.742.30100,924,500.003.966.524.397.3544.4649.558.9717.985.19--0.0024.1711.74-2.674.4428.76-20.3820.11
Towa Pharmaceutical Co Ltd243.94bn15.78bn145.64bn4.59k8.820.87474.210.597320.50320.504,956.023,232.160.58381.523.9353,169,570.003.784.214.565.6336.1039.236.477.231.63--0.58121.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd81.07bn10.73bn182.70bn1.78k15.330.745611.962.25241.71241.711,825.834,969.030.32941.602.9845,568,860.004.383.614.753.9049.8849.4713.3112.694.15--0.005734.8711.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.87.25bn18.24bn203.74bn1.14k9.211.099.752.34481.71481.712,303.804,076.800.48641.983.8876,867,840.0010.176.8311.667.8760.6654.7820.9114.484.47--0.024351.25-1.29-5.2147.52-14.700.36390.00
Sumitomo Pharma Co Ltd342.67bn-279.46bn235.95bn4.98k--2.06--0.6886-703.41-703.41862.50287.370.35171.304.2868,808,230.00-28.68-5.07-51.21-7.7359.5669.99-81.54-12.280.424-12.100.7732---43.38-7.29-322.71--4.02--
Sawai Group Holdings Co Ltd177.34bn16.55bn255.97bn3.48k15.381.209.021.44126.61184.411,357.791,623.190.46581.122.8350,929,920.003.170.71044.240.970530.7335.086.801.471.3938.130.316988.138.04-0.824946.82-2.3318.150.00
Nippon Shinyaku Co., Ltd.154.27bn26.05bn282.27bn2.21k10.391.158.931.83386.74386.742,290.533,486.810.59561.293.3669,711,700.0010.0610.4511.3912.3167.6961.2716.8916.474.22--0.010732.622.835.2613.329.6645.9312.12
Hisamitsu Pharmaceutical Co Inc150.19bn14.65bn360.59bn2.76k21.691.1417.292.40195.20195.201,996.173,730.090.43233.013.2254,434,580.004.364.225.254.8256.4258.6210.1010.033.14--0.00453.0510.42-0.238518.97-6.1728.900.5989
Tsumura & Co164.61bn25.20bn375.12bn4.14k14.721.269.792.28331.93331.932,167.873,875.470.37830.69162.4839,781,050.006.234.817.635.8948.7650.9816.4812.653.04--0.180632.167.714.521.372.7417.545.84
Santen Pharmaceutical Co Ltd302.56bn26.13bn606.64bn3.74k22.692.0113.662.0173.4673.46846.14827.650.72382.583.6880,812,770.006.253.317.774.1057.9259.738.645.211.975.380.163982.218.225.23278.09-3.585.104.88
Rohto Pharmaceutical Co Ltd282.05bn27.26bn641.93bn7.26k22.802.4517.642.28119.22119.221,233.691,109.160.7592.184.1238,855,630.007.378.5410.2911.7957.3858.599.7110.301.29--0.144219.3913.488.0917.2825.855.2018.61
Ono Pharmaceutical Co Ltd484.30bn95.13bn870.22bn3.85k8.671.057.691.80201.26201.261,026.051,665.850.49872.373.47125,694,000.009.8011.9511.1613.7375.3874.1119.6523.892.80--0.170232.2512.4111.7313.5319.95-6.7912.20
Data as of Nov 22 2024. Currency figures normalised to Santen Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

27.76%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 31 May 202419.14m5.26%
Silchester International Investors LLPas of 19 Apr 202418.29m5.03%
Black Creek Investment Management, Inc.as of 15 Oct 202413.74m3.77%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Aug 202311.34m3.12%
The Vanguard Group, Inc.as of 06 Nov 20249.80m2.69%
Nikko Asset Management Co., Ltd.as of 31 Aug 20238.20m2.25%
Norges Bank Investment Managementas of 30 Jun 20247.38m2.03%
Daiwa Asset Management Co. Ltd.as of 31 Oct 20245.27m1.45%
Massachusetts Financial Services Co.as of 30 Sep 20243.97m1.09%
BlackRock Fund Advisorsas of 07 Nov 20243.90m1.07%
More ▼
Data from 30 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.